KBC Group’s Acadia Pharmaceuticals ACAD Stock Holding History

KBC Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$92K	Hold	3,619	–	–	﹤0.01%	1467
2026 Q1	$81K	Hold	3,619	–	–	﹤0.01%	1444
2025 Q4	$97K	Hold	3,619	–	–	﹤0.01%	1300
2025 Q3	$77K	Hold	3,619	–	–	﹤0.01%	1422
2025 Q2	$78K	Sell	3,619 -1,474	-29%	-$27.4K	﹤0.01%	1360
2025 Q1	$85K	Hold	5,093	–	–	﹤0.01%	1574
2024 Q4	$93K	Buy	5,093 +2,044	+67%	+$33K	﹤0.01%	1602
2024 Q3	$47K	Hold	3,049	–	–	﹤0.01%	1733
2024 Q2	$50K	Buy	+3,049	New	+$49.2K	﹤0.01%	1609
2024 Q1	–	Sell	-2,659	Closed	-$83K	–	1845
2023 Q4	$83K	Hold	2,659	–	–	﹤0.01%	1162
2023 Q3	$55K	Buy	+2,659	New	+$72.2K	﹤0.01%	1364

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

KBC Group's ACAD Position: Q2 2026 in Review

KBC Group held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 3,619 shares worth $92K. The position accounts for ﹤0.01% of the portfolio, ranked #1467.

KBC Group first reported a position in ACAD in Q3 2023 and has held it in 11 quarters since. The position peaked at $97K in Q4 2025. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

KBC Group held 3,619 shares of Acadia Pharmaceuticals worth $92K as of Q2 2026.
KBC Group left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
Acadia Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1467 holding.
KBC Group first reported a position in Acadia Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
KBC Group's Acadia Pharmaceuticals position peaked at $97K in Q4 2025.
353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.